glp-1 nejm publishes Phase 3 trial results for orforglipron, an oral obesity medication. | Scott Isaacs, MD, FACP, FACE posted on the topic Semaglutide in Patients with Heart

BPC-157, for instance, has been shown to enhance growth hormone receptors in tendons, which can significantly speed up the healing of connective tissues

But if you often punch the throttle, the difference becomes very noticeable

34% of patients achieved more than 15% weight loss compared to 3% on placebo

LNCaP-AI cells have higher ATF6 expression than LNCap-A cells

None of them are universally better. They solve overlapping but distinct problems, and the right answer changes with your skin, your budget, and your downtime tolerance

Behavioral Shifts and Key Opportunities Unsurprisingly, GLP-1 drugs are transforming F&B purchasing patterns in numerous ways